摘要
目的:确定盘龙七及其同名异物药材大盘龙七的差异性成分并建立其含量测定方法。方法:采用偏最小二乘法-判别分析(PLS-DA)结合超高效液相色谱-四极杆-飞行时间质谱法(UPLC-Q-TOF-MS)分析盘龙七和大盘龙七差异性成分,并建立差异性成分定性、定量分析方法。结果:PLS-DA结果显示以t检验(P<0.05)和变量重要性投影(VIP)值(VIP>1.0)为标准,筛选出盘龙七和大盘龙七差异性成分共296个。对排名靠前的差异性成分进行表征分析,进一步筛选出符合碎片裂解规律及文献记载的差异性成分共8个,其中绿原酸、没食子酸、岩白菜素3个成分含量差异最显著。结论:该方法能有效分析盘龙七和大盘龙七的差异性,为盘龙七及大盘龙七的质量评价及定性、定量分析提供参考。
Objective:To identify the differential components and establish a methodology for content determination of Polygonum milletii and its homonym herb Bergenia scopulosa.Methods:Partial least squares discriminant analysis(PLS-DA)combined with ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry(UPLC-Q-TOF-MS)was used to analyze the differential components of P.milletii and B.scopulosa and to establish a methodology for their qualitative and quantitative determination.Results:The PLS-DA results showed that 296 differential components of P.milletii and B.scopulosa were identified using the t-test(P<0.05)and VIP value(VIP>1.0)as criteria.The top-ranked differential components were characterized and analyzed,resulting in the identification of eight differential components that conformed to fragmentation patterns and literature.Among these,the content differences in three components,i.e.,chlorogenic acid,gallic acid,and bergenin,were the most significant.Conclusion:This method can effectively analyze the differences between P.milletii and B.scopulosa and provide a reference for the quality evaluation and qualitative and quantitative analysis of P.milletii and B.scopulosa.
作者
何姬
刘妍如
段金廒
唐志书
宋忠兴
赵艳婷
游雪莲
张德柱
杨国伟
张丽
权伟
HE Ji;LIU Yan-ru;DUAN Jin-ao;TANG Zhi-shu;SONG Zhong-xing;ZHAO Yan-ting;YOU Xue-lian;ZHANG De-zhu;YANG Guo-wei;ZHANG Li;QUAN Wei(Shaanxi University of Chinese Medicine/Shaanxi Chinese Medicine Resources Industrialization Collaborative Innovation Center,Xianyang 712083,China;Jiangsu Key Laboratory for High Technology Research of TCM Formulae Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization,Nanjing University of Chinese Medicine,Nanjing 210023,China;School of Chinese Materia Medica.Beijing University of Chinese Medicine,Beijing 100700,China;Shaanxi Panlong Pharmaceutical Group Co.,Ltd.,Shangluo 711400,China;Shanxi Inspection and Testing Center(Shanxi Institute of Standards and Metrology),Taiyuan 030002,China;Department of Pharmacy,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China)
出处
《中国现代中药》
CAS
2024年第9期1520-1527,共8页
Modern Chinese Medicine
基金
陕西省重点研发计划项目(2020ZDLSF05-08)
陕西省高层次人才特殊支持计划项目(陕组通字〔2018〕33号)。